Alexsander Santiago: When Was Your ECMO Anticoagulation Target Last Challenged?
Alexsander Santiago, Health Education Coordinator at Terapia Intensiva em Foco, shared a post on LinkedIn:
”When was your ECMO anticoagulation target last challenged?
RATE gives that question a randomized evidence base.
The Lancet trial enrolled 330 adults across seven Dutch ICUs; 320 were analyzed. It included VV and VA ECMO, excluding patients with a separate vital indication for full-dose anticoagulation.
Three strategies:
- Standard unfractionated heparin: aPTT two to two and a half times the baseline.
- Lower-target unfractionated heparin: aPTT one and a half to two times the baseline.
- Therapeutic subcutaneous low-molecular-weight heparin.
The primary composite combined severe bleeding and severe thromboembolism during ECMO with mortality at six months.
It occurred in 81 percent, 72 percent and 75 percent, respectively.
Both alternatives met noninferiority within the prespecified 7.5-percentage-point margin.
Bleeding was numerically lower; a statistically significant reduction was not demonstrated. RATE, The Lancet, 2026.
My reading: this supports a serious review of anticoagulation defaults, with careful attention to who the evidence applies to.
Noninferiority for a composite does not establish equivalent protection against every component.
Therapeutic LMWH also represents a distinct strategy, making ‘less heparin’ an incomplete description of the trial.
For an ECMO programme, I would bring four questions to the protocol review:
- Which patients match the trial population?
- What justifies the target for this patient today?
- Which findings should trigger reassessment?
- How will we review bleeding, thrombosis and circuit exchanges separately?
A revised target needs explicit exceptions, shared bedside judgment and an audit of what happens after implementation.
The useful institutional change would be to make the reasoning behind each target visible, with reassessment built into routine care.
What would RATE change first in your unit: the default target, patient selection or monitoring?”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration
-
Oct 17, 2026, 16:43Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period